The founding member of the INK4 family of cyclin-dependent kinase inhibitors, which arrests the cell cycle in G1 by directly binding CDK4 and CDK6 and blocking phosphorylation of the retinoblastoma (Rb) tumor suppressor. Cloned in 1993 by Manuel Serrano, Gregory Hannon, and David Beach as a specific inhibitor of cyclin D/CDK4, p16INK4a is both one of the most frequently inactivated tumor suppressors in human cancer and the master molecular biomarker and effector of irreversible cellular senescence.
Gene
CDKN2A (chromosome 9p21.3; shares exons 2–3 in an alternative reading frame with p14ARF)
Family
INK4 (INhibitors of CDK4) cell-cycle inhibitor family (alongside p15INK4b / CDKN2B, p18INK4c, p19INK4d)
156 amino acids (~16.5 kDa, UniProt P42771); four tandem helix-turn-helix ankyrin repeats
Binding Partners
Monomeric CDK4 and CDK6 (competing with D-type cyclins and preventing Rb phosphorylation)
Structure
Human p16INK4a is a compact 156-amino-acid protein folded into four stacked ankyrin repeat motifs connected by beta-hairpin loops, lacking disulfides or prosthetic groups.
Its parent locus, CDKN2A on chromosome 9p21.3, exhibits a remarkable dual-coding organization: p16INK4a is transcribed from exon 1α spliced to shared exons 2 and 3, whereas an upstream promoter transcribes exon 1β spliced to the same exons 2 and 3 in an shifted reading frame to produce the structurally unrelated protein p14ARF (which stabilizes p53 by inhibiting MDM2).
Function
In proliferating cells, mitogenic signals induce D-type cyclins that assemble with CDK4 and CDK6 to phosphorylate Rb (encoded by RB1), releasing E2F transcription factors to transcribe S-phase genes. p16INK4a binds directly to CDK4 and CDK6 opposite their catalytic cleft, allosterically distorting the ATP-binding pocket and blocking cyclin D association. Kept hypophosphorylated, Rb remains tightly bound to E2F in the nucleus, enforcing a durable G1 cell-cycle arrest.
Regulation
In young, unstressed tissues, the CDKN2A locus is epigenetically silenced by Polycomb Repressive Complex 1 and 2 via Histone H3 lysine-27 trimethylation (H3K27me3), guided in part by the antisense long non-coding RNA ANRIL (CDKN2B-AS1).
Replicative telomere attrition, oncogenic RAS (KRAS / HRAS) signaling, and chronic oxidative stress derepress the promoter, driving progressive exponential accumulation of p16INK4a mRNA and protein across aging mammalian tissues.
Interactions
While p21 (CDKN1A) mediates the rapid, reversible initial arrest downstream of p53 after acute DNA damage, p16INK4a locks cells into the irreversible G1 arrest of cellular senescence.
In 2016, Darren Baker, Jan van Deursen, and colleagues demonstrated using INK-ATTAC transgenic mice that inducible clearance of p16Ink4a-positive senescent cells extends median lifespan and delays age-related kidney, heart, and adipose tissue dysfunction.
Clinical Relevance
Oncology: Homozygous deletion, point mutation, or promoter CpG hypermethylation of CDKN2A occurs in pancreatic adenocarcinoma, glioblastoma, melanoma (including familial atypical multiple mole melanoma syndrome), and non-small-cell lung cancer.
Pharmacology & diagnostics: Synthetic CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib) act as small-molecule pharmacological mimics of p16INK4a in hormone-receptor-positive breast cancer, while diffuse p16 immunohistochemistry serves as the clinical surrogate marker for high-risk HPV E7-driven inactivation of Rb in cervical and oropharyngeal carcinomas.